Latest News

Wednesday December 22, 2021

We welcome our new ASI Sustaining Member: AbbVie

AbbVie is proud to be named as a Sustaining Member of the Australian and New Zealand Society for Immunology (ASI). As a company that aims to make a remarkable impact on the lives of patients, advancing the science and education of immunology is a shared goal.

We are highly committed to developing and maintaining partnerships that ultimately benefit patients and fuel scientific progress. To create innovative solutions that go beyond treating the illness to have a positive impact on people’s lives, society – and science itself.

Science and innovation are the cornerstones of our business. Since 2013, AbbVie has invested over $50 billion in R&D along the research continuum of discovery, genomics, translational, precision medicine and clinical research. In Australia and New Zealand alone, AbbVie invests $31 million annually in clinical research funding. Over 2000 patients are participating in AbbVie funded trials, with 64 Phase III trials currently active of which 29 are in immunology.

At AbbVie we see a future of possibilities and we are investing accordingly. An additional 80 plus trials will commence in the next 2 years across Australia and New Zealand - 20 will be in immunology.

It’s the combination of great people and strong partnerships that enable us to build on the best ideas, wherever they originate. We look forward to our continued partnership with the ASI.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. Our heritage in Australia reaches back more than 80 years and we employ more than 450 people with our therapies currently benefiting more than 40,000 Australians. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments. Recently, we acquired Allergan which immediately diversified our business across several therapeutic areas: Immunology, Oncology, Virology, Neuroscience, Eye Care and Aesthetics.

For further information please visit Follow @abbvie_AU on Twitter, FacebookInstagram or our LinkedIn page.

Learn more about AbbVie

Learn more about the ASI AbbVie New Horizons Research Award

Back to All Blogs

© ASI 2021

ABN 76 330 189 856 | ARBN 084 971 559 | CAV A0016266B